DiaSorin Company Description
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally.
It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name.
The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens.
In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay.
Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Country | Italy |
Founded | 1968 |
Industry | In Vitro and In Vivo Diagnostic Substances |
Employees | 3,308 |
CEO | Carlo Rosa |
Contact Details
Address: Via Crescentino snc Saluggia, Vercelli 13040 Italy | |
Phone | 39 016 1487526 |
Website | int.diasorin.com |
Stock Details
Ticker Symbol | DIAS |
Exchange | Vienna Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | EUR |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Carlo Rosa | Chief Executive Officer |
Piergiorgio Pedron | Chief Financial Officer |
Riccardo Fava | Head of Investor Relations |